Top

Neurological Sciences

Published in:

01-07-2021 | Alzheimer's Disease | Original Article

Do serum GDNF levels correlate with severity of Alzheimer’s disease?

Authors: Maryam Sharif, Maryam Noroozian, Farshad Hashemian

Published in: Neurological Sciences | Issue 7/2021

Abstract

Introduction

A growing body of evidence that glial cell line–derived neurotrophic factor (GDNF) levels are probably involved in pathogenesis and disease course of Alzheimer’s disease (AD) suggested that its blood levels could potentially be used as a biomarker of AD. The aim of this study was to compare serum GDNF levels in patients with AD and age-matched controls.

Methods

Serum concentrations of GDNF were compared in 25 AD patients and 25 healthy volunteers using a double-antibody sandwich enzyme-linked immunosorbent assay (ELISA). Severity of the disease in AD patients was assessed using Functional Assessment Staging (FAST). Cognitive assessment of the patients was done using the Mini-Mental State Examination (MMSE).

Results

Mean GDNF levels were found to be 2.45 ± 0.93 ng/ml in AD patients and 4.61 ± 3.39 ng/ml in age-matched controls. There was a statistically significant difference in GDNF serum levels in patients with AD compared to age-matched controls (p = 0.001). Moreover, GDNF serum levels were significantly correlated with disease severity (p < 0.001) and cognitive impairment (p < 0.001).

Conclusion

This study showed that serum levels of GDNF are significantly decreased in AD patients in comparison with age-matched controls, thus suggesting a potential role of GDNF as a disease biomarker. However, a comprehensive study of changes in serum levels of multiple neurotrophic factors reflective of different neurobiological pathways in large-scale population studies is recommended.

Prince M, Ali GC, Guerchet M, Prina AM, Albanese E, Wu YT (2016) Recent global trends in the prevalence and incidence of dementia, and survival with dementia. Alzheimers Res Ther 8:23PubMedPubMedCentral

Hebert LE, Weuve J, Scherr PA, Evans DA (2013) Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology 80:1778–1783PubMedPubMedCentral

Prince M, Guerchet M, Prina M (2013) Policy brief for heads of government: the global impact of dementia 2013–2050. Alzheimer's Disease International, London https://www.alz.co.uk/research/GlobalImpactDementia2013.pdf. Accessed 20 Sept 2020

Adlimoghaddam A, Roy B, Albensi BC (2018) Future trends and the economic burden of dementia in Manitoba: comparison with the rest of Canada and the world. Neuroepidemiology 51:71–81PubMed

Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M, Alzheimer's Disease International (2005) Global prevalence of dementia: a Delphi consensus study. Lancet 366:2112–2117PubMedPubMedCentral

Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E (2011) Alzheimer’s disease. Lancet 377:1019–1031PubMed

Krashia P, Nobili A, D'Amelio M (2019) Unifying hypothesis of dopamine neuron loss in neurodegenerative diseases: focusing on Alzheimer’s disease. Front Mol Neurosci 12:123PubMedPubMedCentral

Selkoe DJ (2002) Alzheimer’s disease is a synaptic failure. Science 298:789–791

Vyas Y, Montgomery JM, Cheyne JE (2020) Hippocampal deficits in amyloid-β-related rodent models of Alzheimer’s disease. Front Neurosci 14:266PubMedPubMedCentral

10.

Marsh J, Alifragis P (2018) Synaptic dysfunction in Alzheimer’s disease: the effects of amyloid beta on synaptic vesicle dynamics as a novel target for therapeutic intervention. Neural Regen Res 13:616–623PubMedPubMedCentral

11.

Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, Wölfing H, Chieng BC, Christie MJ, Napier IA, Eckert A, Staufenbiel M, Hardeman E, Götz J (2010) Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer’s disease mouse models. Cell 142:387–397PubMed

12.

Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, Yu GQ, Mucke L (2007) Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer’s disease mouse model. Science 316:750–754PubMed

13.

Angelucci F, Spalletta G, di Iulio F, Ciaramella A, Salani F, Colantoni L, Varsi AE, Gianni W, Sancesario G, Caltagirone C, Bossù P (2010) Alzheimer’s disease (AD) and mild cognitive impairment (MCI) patients are characterized by increased BDNF serum levels. Curr Alzheimer Res 7:15–20PubMed

14.

Duan Y, Dong S, Gu F, Hu Y, Zhao Z (2012) Advances in the pathogenesis of Alzheimer’s disease: focusing on tau-mediated neurodegeneration. Transl Neurodegener 1:24PubMedPubMedCentral

15.

Tapia-Arancibia L, Aliaga E, Silhol M, Arancibia S (2008) New insights into brain BDNF function in normal aging and Alzheimer disease. Brain Res Rev 59:201–220PubMed

16.

Schindowski K, Belarbi K, Buee L (2008) Neurotrophic factors in Alzheimer’s disease: role of axonal transport. Genes Brain Behav 1:43–56

17.

Budni J, Bellettini-Santos T, Mina F, Garcez ML, Zugno AI (2015) The involvement of BDNF, NGF and GDNF in aging and Alzheimer’s disease. Aging Dis 6:331–341PubMedPubMedCentral

18.

O'Bryant SE, Hobson V, Hall JR, Waring SC, Chan W, Massman P, Lacritz L, Cullum CM, Diaz-Arrastia R, Texas Alzheimer’s Research Consortium (2009) Brain-derived neurotrophic factor levels in Alzheimer’s disease. J Alzheimers Dis 17:337–341PubMedPubMedCentral

19.

Mattson MP, Maudsley S, Martin B (2004) BDNF and 5-HT: a dynamic duo in age- related neuronal plasticity and neurodegenerative disorders. Trends Neurosci 27:589–594PubMed

20.

Mitra S, Behbahani H, Eriksdotter M (2019) Innovative therapy for Alzheimer’s disease-with focus on biodelivery of NGF. Front Neurosci 5:13–38

21.

Deister C, Schmidt CE (2006) Optimizing neurotrophic factor combinations for neurite outgrowth. J Neural Eng 3:172–179PubMed

22.

Cheng H, Fu YS, Guo JW (2004) Ability of GDNF to diminish free radical production leads to protection against kainate-induced excitotoxicity in hippocampus. Hippocampus 14:77–86PubMed

23.

Mätlik K, Võikar V, Vilenius C, Kulesskaya N, Andressoo JO (2018) Two-fold elevation of endogenous GDNF levels in mice improves motor coordination without causing side-effects. Sci Rep 8:11861PubMedPubMedCentral

24.

Pertusa M, García-Matas S, Mammeri H, Adell A, Rodrigo T, Mallet J, Cristòfol R, Sarkis C, Sanfeliu C (2008) Expression of GDNF transgene in astrocytes improves cognitive deficits in aged rats. Neurobiol Aging 29:1366–1379PubMed

25.

Forlenza OV, Miranda AS, Guimar I, Talib LL, Diniz BS, Gattaz WF, Teixeira AL (2015) Decreased neurotrophic support is associated with cognitive decline in non-demented subjects. J Alzheimers Dis 46:423–429PubMed

26.

Airavaara M, Pletnikova O, Doyle ME, Zhang YE, Troncoso JC, Liu QR (2011) Identification of novel GDNF isoforms and cis-antisense GDNFOS gene and their regulation in human middle temporal gyrus of Alzheimer disease. J Biol Chem 286:45093–45102PubMedPubMedCentral

27.

Ghribi O, Herman MM, Forbes MS, DeWitt DA, Savory J (2001) GDNF protects against aluminum-induced apoptosis in rabbits by upregulating Bcl-2 and Bcl-XL and inhibiting mitochondrial Bax translocation. Neurobiol Dis 8:764–773PubMed

28.

Lee JG, Shin BS, You YS, Kim JE, Yoon SW, Jeon DW, Baek JH, Park SW, Kim YH (2009) Decreased serum brain-derived neurotrophic factor levels in elderly Korean with dementia. Psychiatry Investig 6:299–305PubMedPubMedCentral

29.

Laske C, Stransky E, Leyhe T, Eschweiler GW, Maetzler W, Wittorf A, Soekadar S, Richartz E, Koehler N, Bartels M, Buchkremer G, Schott K (2007) BDNF serum and CSF concentrations in Alzheimer’s disease, normal pressure hydrocephalus and healthy controls. J Psychiatr Res 41:387–394PubMed

30.

Laske C, Stransky E, Leyhe T, Eschweiler GW, Wittorf A, Richartz E, Bartels M, Buchkremer G, Schott K (2006) Stage-dependent BDNF serum concentrations in Alzheimer's disease. J Neural Transm 113:1217–1224PubMed

31.

McKhann GM (2011) The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7:263–269PubMedPubMedCentral

32.

Sclan SG, Reisberg B (1992) Functional assessment staging (FAST) in Alzheimer’s disease: reliability, validity, and ordinality. Int Psychogeriatr 4:55–69PubMed

33.

Reisberg B, Wegiel J, Franssen E, Monteiro I, Torossian C, Anwar S, Gill T, Boksay I, Auer S, Shimada M, Meguro K (2011) The Fast: a brief, practical, comprehensive, valid functional assessment for Alzheimer’s disease staging, diagnosis and differential diagnosis in the primary care setting. Alzheimers Dement 7:S82

34.

Ansari NN, Naghdi S, Hasson S, Valizadeh L, Jalaei (2010) Validation of a mini-mental state examination (MMSE) for the Persian population: a pilot study. Appl Neuropsychol 17:190–195PubMed

35.

Gunstad J, Benitez A, Smith J, Glickman E, Spitznagel MB, Alexander T, Juvancic-Heltzel J, Murray L (2008) Serum brain-derived neurotrophic factor is associated with cognitive function in healthy older adults. J Geriatr Psychiatry Neurol 21:166–170PubMed

36.

Fielder GC, Wen-Shan Yang T, Razdan M, Li Y, Lu J, Perry JK, Lobie PE, Liu DX (2018) The GDNF family: a role in cancer? Neoplasia 20:99–117PubMed

37.

Straten G, Eschweile GW, Maetzler W, Laske C, Leyhe T (2009) Glial cell-line derived neurotrophic factor (GDNF) concentrations in cerebrospinal fluid and serum of patients with early Alzheimer’s disease and normal controls. J Alzheimers Dis 18:331–337PubMed

38.

Konishi Y, Yang LB, He P, Lindholm K, Lu B, Li R, Shen Y (2014) Deficiency of GDNF receptor GFRα1 in Alzheimer’s neurons results in neuronal death. J Neurosci 34:13127–13138PubMedPubMedCentral

39.

Faria MC, Goncalves GS, Rocha NP, Moraes EN, Bicalho MA, Gualberto MT, Jardim de Paula J, José Ravic de Miranda LF, Clayton de Souza Ferreira A, Teixeira AL, Gomes KB, Carvalho M, Sousa LP (2014) Increased plasma levels of BDNF and inflammatory markers in Alzheimer’s disease. J Psychiatr Res 53:166–172PubMed

40.

Borba EM, Duarte JA, Bristot G, Scotton E, Camozzato AL, Fagundes Chaves ML (2016) Brain-derived neurotrophic factor serum levels and hippocampal volume in mild cognitive impairment and dementia due to Alzheimer disease. Dement Geriatr Cogn Dis Extra 6:559–567PubMedPubMedCentral

41.

Leyhe T, Stransky E, Eschweiler GW, Buchkremer G, Laske C (2008) Increase of BDNF serum concentration during donepezil treatment of patients with early Alzheimer’s disease. Eur Arch Psychiatry Clin Neurosci 258:124–128PubMed

42.

Gezen-Ak D, Dursun E, Hanağasi H, Bilgiç B, Lohman E, Araz OS, Atasoy IL, Alaylıoğlu M, Önal B, Gürvit H, Yılmazer S (2013) BDNF, TNFα, HSP90, CFH, and IL- 10 serum levels in patients with early or late onset Alzheimer’s disease or mild cognitive impairment. J Alzheimers Dis 37:185–195PubMed

43.

Janel N, Alexopoulos P, Badel A, Lamari F, Camproux AC, Lagarde J, Simon S, Feraudet-Tarisse C, Lamourette P, Arbones M, Paul JL, Dubois B, Potier MC, Sarazin M, Delabar JM (2017) Combined assessment of DYRK1A, BDNF and homocysteine levels as diagnostic marker for Alzheimer’s disease. Transl Psychiatry 7:e1154PubMedPubMedCentral

44.

Woolley JD, Strobl EV, Shelly WB, Karydas AM, Robin Ketelle RN, Wolkowitz OM, Miller BL, Rankin KP (2012) BDNF serum concentrations show no relationship with diagnostic group or medication status in neurodegenerative disease. Curr Alzheimer Res 9:815–821PubMedPubMedCentral

45.

Sonali N, Tripathi M, Sagar R, Vivekanandhan S (2013) Val66Met polymorphism and BDNF levels in Alzheimer’s disease patients in north Indian population. Int J Neurosci 123:409–416PubMed

46.

Ted NG, Ho CS, Tam W, Kua EH, Ho RC (2016) Serum brain-derived neurotrophic factors (BDNF) levels in patients with Alzheimer’s disease (AD), individuals with mild cognitive impairment (MCI) and healthy controls: a systematic review, meta-analysis, and meta-regression. Alzheimers Dement 12:1181

47.

Balietti M, Giuli C, Fattoretti P, Fabbietti P, Papa R, Postacchini D, Conti F (2017) Effect of a comprehensive intervention on plasma BDNF in patients with Alzheimer’s disease. J Alzheimers Dis 57:7–43

48.

Konukoglu D, Andican G, Fırtına S, Erkol G, Kurt A (2012) Serum brain-derived neurotrophic factor, nerve growth factor and neurotrophin-3 levels in dementia. Acta Neurol Belg 112:255–260PubMed

49.

Pláteník J, Fišar Z, Buchal R, Jirák R, Kitzlerová E, Zvěřová M, Raboch J (2014) GSK3β, CREB, and BDNF in peripheral blood of patients with Alzheimer’s disease and depression. Prog Neuro-Psychopharmacol Biol Psychiatry 3:83–93

50.

Ziegenhorn AA, Schulte-Herbrüggen O, Danker-Hopfe H, Malbranc M, Hartung HD, Anders D, Lang UE, Steinhagen-Thiessen E, Schaub RT, Hellweg R (2007) Serum neurotrophins--a study on the time course and influencing factors in a large old age sample. Neurobiol Aging 28:1436–1445PubMed

51.

Wilson RS, Arnold SE, Beck TL, Bienias JL, Bennett DA (2008) Change in depressive symptoms during the prodromal phase of Alzheimer disease. Arch Gen Psychiatry 65:439–445PubMed

Title: Do serum GDNF levels correlate with severity of Alzheimer’s disease?
Authors: Maryam Sharif
Maryam Noroozian
Farshad Hashemian
Publication date: 01-07-2021
Publisher: Springer International Publishing
Keywords: Alzheimer's Disease
Alzheimer's Disease
Published in: Neurological Sciences / Issue 7/2021
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-020-04909-1

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Do serum GDNF levels correlate with severity of Alzheimer’s disease?

Abstract

Introduction

Methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 7/2021

Association between subjective autonomic dysfunction and fatigue in Parkinson’s disease in southern Chinese

Effect of whole-body vibration on freezing and flexibility in Parkinson’s disease—a pilot study

A novel task-specific dystonia: running-induced cervical dystonia in a triathlete

Different functional connectivity modes of the right fronto-insular cortex in akinetic-rigid and tremor-dominant Parkinson’s disease

Association between freezing of gait and bone mineral density in patients with Parkinson’s disease

Migraine and handedness